Merck & Co Inc
MRK: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$391.00 | Ggzqd | Mddgnwwz |
Merck Posts Strong Q2, Buoyed by Easy Comparisons and Robust Keytruda and Gardasil Gains
Merck reported strong second-quarter results ahead of our projections, but we do not expect any major changes to our fair value estimate based on the minor outperformance. With the strong stock performance over the past few months, we now view the stock as only slightly undervalued, with the market better appreciating the growth potential of the firm’s current portfolio and pipeline, the keys pillars to Merck’s wide moat.